EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Noronha, Vanita ^a   Prabhash, Kumar ^a   Thavamani, Abhishek ^a   Chougule, Anuradha ^a   Purandare, Nilendu ^a   Joshi, Amit ^a   Sharma, Rashmi ^a   Desai, Saral ^a   Jambekar, Nirmala ^a   Dutt, Amit ^a   Mulherkar, Rita ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INDIAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; POINT MUTATION; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SKIN TOXICITY; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING; WILD TYPE;

ADMINISTRATION, ORAL; DEMOGRAPHY; FEMALE; GENETIC TESTING; HUMANS; INDIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84876447147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061561     Document Type: Article

References (16)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2011) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
3. Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, et al. (2005) The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 16: 1334-1342.
4. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
6. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
7. Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, et al. (2011) Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73: 316-319.
8. Krishnamurthy A, Vijayalakshmi R, Gadigi V, Ranganathan R, Sagar TG, (2012) The relevance of "Nonsmoking-associated lung cancer" in India: a single-centre experience. Indian J Cancer 49: 82-88.
9. Noronha V, Dikshit R, Raut N, Joshi A, Pramesh CS, et al. (2012) Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience. Indian J Cancer 49: 74-81.
10. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, et al. (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16: 1081-1086.
11. Dong J, Hu Z, Wu C, Guo H, Zhou B, et al. (2012) Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet 44: 895-899.
12. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
13. Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, et al. (2010) Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6: 28-31.
14. Han JY, Park K, Kim SW, Lee DH, Kim HY, et al. (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30: 1122-1128.
15. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, et al. (2008) Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26: 2745-2753.
16. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.